Investing.comCodex · 实盘不做把握 6/10
北京时间·🕒 发布 07-23 19:12:30时区推断·⟳ 抓取 07-23 19:19:03·⚡ 决策 07-24 08:24:28 +13h05m·95.4 天前
Viking Therapeutics任命Dorothy Gemmell进入董事会
正文实际是Viking任命商业化背景董事，而非标题中的Google AI支出事项。
📄 原文Investing.com↗ 原文
Viking Therapeutics adds Dorothy Gemmell to board of directors
Google raises annual spending estimates amid rapid AI infrastructure build-out SAN DIEGO - Viking Therapeutics, Inc. (N…
不做 Viking Therapeutics（VKTX.US）
正文是董事任命且标题混入无关Google支出，未形成VKTX.US短期收入、临床或监管催化，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-23 · 扩散 low · price-in 风险 medium ↗
关键理由
- 正文实际是Viking任命商业化背景董事，而非标题中的Google AI支出事项。
主要风险
- 董事任命通常不直接改变VK2735临床进度、监管概率或短期商业化现金流。
工具调用 · 历史记录,结果未知(2 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
原文全文
展开原文 · 1,611 字
Google raises annual spending estimates amid rapid AI infrastructure build-out
SAN DIEGO - Viking Therapeutics, Inc. (NASDAQ:VKTX) announced today the appointment of Dorothy Gemmell to its Board of Directors, effective immediately, according to a press release statement.
Gemmell brings over 25 years of experience in healthcare, digital health, and commercialization. She has held president or chief commercial officer positions at GoodRx, Capsule, and Havas Life. She holds a Bachelor of Science in biochemistry from McGill University.
The company is a clinical-stage biopharmaceutical firm focused on developing therapies for metabolic and endocrine disorders. Its lead program, VK2735, is a dual GLP-1 and GIP receptor agonist being developed in both subcutaneous and oral formulations for obesity. VK2735 is currently in Phase 3 clinical studies for obesity and a Phase 1 study evaluating maintenance dosing strategies.
"Dorothy joins our Board as Viking advances its next-generation therapies, prepares for VK2735’s potential launch, and strengthens our commercialization capabilities," said Brian Lian, chief executive officer of Viking Therapeutics.
The company’s pipeline also includes VK3019, an amylin receptor agonist, VK2809, a thyroid hormone receptor beta agonist for metabolic and liver disease, and VK0214 for X-linked adrenoleukodystrophy.
Lawson Macartney, Viking’s chairman, stated that Gemmell’s commercial expertise complements the Board’s pharmaceutical development experience.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
SAN DIEGO - Viking Therapeutics, Inc. (NASDAQ:VKTX) announced today the appointment of Dorothy Gemmell to its Board of Directors, effective immediately, according to a press release statement.
Gemmell brings over 25 years of experience in healthcare, digital health, and commercialization. She has held president or chief commercial officer positions at GoodRx, Capsule, and Havas Life. She holds a Bachelor of Science in biochemistry from McGill University.
The company is a clinical-stage biopharmaceutical firm focused on developing therapies for metabolic and endocrine disorders. Its lead program, VK2735, is a dual GLP-1 and GIP receptor agonist being developed in both subcutaneous and oral formulations for obesity. VK2735 is currently in Phase 3 clinical studies for obesity and a Phase 1 study evaluating maintenance dosing strategies.
"Dorothy joins our Board as Viking advances its next-generation therapies, prepares for VK2735’s potential launch, and strengthens our commercialization capabilities," said Brian Lian, chief executive officer of Viking Therapeutics.
The company’s pipeline also includes VK3019, an amylin receptor agonist, VK2809, a thyroid hormone receptor beta agonist for metabolic and liver disease, and VK0214 for X-linked adrenoleukodystrophy.
Lawson Macartney, Viking’s chairman, stated that Gemmell’s commercial expertise complements the Board’s pharmaceutical development experience.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。